Definium Therapeutics, Inc. (DFTX) intrinsic value & 10-year financials
Definium Therapeutics, Inc. (DFTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $32.10
- Market cap
- $2.9B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 330.2%
- Free cash flow (FY2025)
- —
DFTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$183.8M | -$2.06 | — | — | -317.9% |
| FY2024 | — | -$108.7M | -$1.54 | — | — | 1215.6% |
| FY2023 | — | -$95.7M | -$2.44 | — | — | 1286.5% |
| FY2022 | — | -$56.8M | -$1.84 | — | — | -37.5% |
| FY2021 | — | -$93.0M | -$3.40 | — | — | -81.5% |
| FY2020 | — | -$33.9M | — | — | — | -84.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Definium Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Definium Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just 7.3% ROIC.
Definium Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Definium Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.